Genfit (EPA:GNFT) Shares Down 4.2% – What’s Next?

Genfit S.A. (EPA:GNFT) shares dropped 4.2% during mid-day trading on Wednesday . The company traded as low as €3.40 ($3.50) and last traded at €3.43 ($3.53). Approximately 257,270 shares changed hands during mid-day trading, The stock had previously closed at €3.58 ($3.69).

Genfit Stock Up 2.0 %

The company has a 50-day moving average price of €4.60 and a 200 day moving average price of €4.28.

Genfit Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.